BioSpace News Archive

Enveric Biosciences today provided a corporate update and reported financial results for the first quarter of 2024 ended March 31, 2024.

Ocugen, Inc. announced that dosing is complete in the second cohort of its Phase 1/2 GARDian clinical trial for OCU410ST —a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment for life.

DarioHealth Corp., a leader in the global digital health market, reported financial results for the first quarter 2024.

aTyr Pharma, Inc. announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society 2024 International Conference, which is scheduled to take place May 17 – 22 in San Diego, CA.

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today provided an update from the Company’s ongoing Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for the prevention of lung transplant rejection.

Oncolytics Biotech today announced that it has entered into a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR).

Vector Laboratories, a manufacturing partner of reagents and critical components for the development and production of life sciences tools, diagnostics, and clinical-stage biotherapeutics, announced its intention to merge with Absolute Biotech, a unified company of multiple antibody-centric brands.

Moleculin Biotech, Inc. today announced the commencement of an Investigator-initiated Phase 2 study evaluating WP1066 in combination with radiation therapy for the treatment of adults with glioblastoma (NU 21C06) in cooperation with the Company.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presents the company’s proprietary T cell receptor discovery process to obtain optimal affinity 3S TCRs at the 21th Association for Cancer Immunotherapy Annual Meeting in Mainz from May 15 - 17, 2024.